Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Invested Capital (2018 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Return on Invested Capital for 6 consecutive years, with 0.18% as the latest value for Q4 2025.

  • Quarterly Return on Invested Capital rose 8.0% to 0.18% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.18% through Dec 2025, up 8.0% year-over-year, with the annual reading at 0.19% for FY2025, 7.0% up from the prior year.
  • Return on Invested Capital hit 0.18% in Q4 2025 for Protagonist Therapeutics, up from 0.25% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.32% in Q1 2024 to a low of 0.31% in Q3 2021.
  • Historically, Return on Invested Capital has averaged 0.04% across 3 years, with a median of 0.24% in 2025.
  • Biggest YoY gain for Return on Invested Capital was 80bps in 2021; the steepest drop was -152bps in 2021.
  • Year by year, Return on Invested Capital stood at 0.31% in 2021, then soared by 131bps to 0.1% in 2024, then skyrocketed by 84bps to 0.18% in 2025.
  • Business Quant data shows Return on Invested Capital for PTGX at 0.18% in Q4 2025, 0.25% in Q3 2025, and 0.24% in Q2 2025.